Search results
- First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model / Kontsekova E. ... [et al.] . Alzheimer's Research & Therapy . - Vol. 6, no. 4 (2014), s. 44 [Dokument nie je vo fonde knižnice]
- Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease / Stozicka Z. ... [et al.] . Journal of Neuroinflammation . - Vol. 7 (2010), s. 64 [Dokument nie je vo fonde knižnice]
- Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial / Novak P. ... [et al.] . The Lancet. Neurology . - Vol. 16, no. 2 (2017), s. 123–134 [Dokument nie je vo fonde knižnice]